A--Pre-Solicitation Notice
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has issued a pre-solicitation notice for the Biological Testing Facility (BTF). This upcoming Indefinite-Delivery, Indefinite-Quantity (IDIQ) cost-reimbursement contract, RFP 75N94026R00005, will support the discovery, chemistry, and development of anti-fertility agents, bridging discovery to development and regulatory approval of contraceptive drugs. The solicitation will be conducted under full and open competition.
Scope of Work
The BTF will encompass the discovery and optimization of compounds as anti-fertility agents and provide comprehensive preclinical support services for male and female contraceptive products. Key requirements include:
- Conducting in vitro enzymatic and cell-based assays.
- Performing in vivo studies, anti-fertility assessments, endocrine activity, toxicity, formulation, and stability testing.
- Executing Absorption Distribution Metabolism Excretion (ADME) and Drug Metabolism Pharmacokinetics (DMPK) profiling for new chemical compounds, delivery systems, and devices.
- Providing biological safety and efficacy evaluations to meet regulatory requirements.
- Assisting in identifying appropriate tests and assays for safety and efficacy.
- Supporting all phases of preclinical development of contraceptives, including process and product development, clinical lot production, formulation, and preclinical enabling studies.
- Assisting in identifying products ready for further development and production.
- Offering information management and Investigational New Drug (IND) preparation and filing support.
Contract Details & Timeline
- Contract Type: Indefinite-Delivery, Indefinite-Quantity (IDIQ), Cost-Reimbursement.
- Period of Performance: Seven (7) year ordering period.
- Anticipated Commencement: On or around September 30, 2026.
- NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)).
- Set-Aside: Full and Open Competition.
- RFP Availability: On or about April 13, 2026.
- Proposal Due Date: On or about May 28, 2026.
- Published Date: March 27, 2026.
Submission & Eligibility
The Request for Proposals (RFP) will be made available electronically via SAM.gov "Contract Opportunities." Offerors are responsible for monitoring the website for the RFP and any subsequent amendments. All inquiries must be submitted electronically. Offerors must be registered in the System for Award Management (SAM) database to be eligible for award.
Additional Notes
This notice serves as a pre-solicitation synopsis and is not a request for proposals or an authorization to commence work. The Government is not soliciting quotes or bids at this time and this notice does not commit the Government to award a contract.